Facebook
Linkedin
Twitter
Industries
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Quick Byte
Resources
Search
Friday, April 4, 2025
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
ReadMagazine
Industries
All
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
How Genomics is Reshaping Personalized Healthcare
Solera Unveils AI-Driven Fleet Management Platform
Culture Biosciences Unveils Stratyx™ 250: The First Cloud-Integrated, Mobile Bioreactor for…
PANTHERx® Rare Expands Patient Support Capabilities for Cell and Gene Therapies…
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Quick Byte
Resources
Home
Tags
BOT/BAL Development
BOT/BAL Development
Biotechnology
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
News Desk
-
April 15, 2024
Agenus Inc., a leader in discovering and developing novel immunological agents to treat various cancers, announced updated results from its Phase 1 clinical trial...
0
Fans
Like
3,912
Followers
Follow
0
Subscribers
Subscribe
Hot Topics
How Genomics is Reshaping Personalized Healthcare
Solera Unveils AI-Driven Fleet Management Platform
Culture Biosciences Unveils Stratyx™ 250: The First Cloud-Integrated, Mobile Bioreactor for Accelerated Cell Culture Development
Load more
